BLCM Bellicum Pharmaceuticals Inc (PK)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Smith Alan K.	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [ BLCM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) EVP, Technical Operations
(Last)          (First)          (Middle) C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800	3. Date of Earliest Transaction (MM/DD/YYYY) 1/2/2020
(Street) HOUSTON, TX 77030 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/2/2020		M		2344	A	(1)	6865	D
Common Stock	1/2/2020		F(2)		883	D	$1.51	5982	D
Common Stock	1/3/2020		M		1563	A	(1)	7545	D
Common Stock	1/3/2020		F(3)		589	D	$1.40	6956	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	1/2/2020		M			2344	(4)	(4)	Common Stock	2344.0	$0	4687	D
Restricted Stock Units	(1)	1/3/2020		M			1563	(5)	(5)	Common Stock	1563.0	$0	1562	D

Explanation of Responses:
(1)	Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock.
(2)	Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 9,375 shares.
(3)	Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 6,250 shares.
(4)	On January 2, 2018, the reporting person was granted 9,375 RSUs, of which 2,344 vested on January 2, 2020. The RSUs vest in four annual installments beginning January 2, 2019.
(5)	On January 3, 2017, the reporting person was granted 6,250 RSUs, of which 1,563 vested on January 3, 2020. The RSUs vest in four annual installments beginning January 3, 2018.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Smith Alan K. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030			EVP, Technical Operations

Signatures
/s/ Alan K. Smith, Ph.D.		1/6/2020
**Signature of Reporting Person		Date